Scopus Biopharma

Scopus Biopharma Total Assets

The Total Assets of Scopus Biopharma (SCPS) as of Nov 16, 2026 is 392,265.00 USD. In the previous year, Total Assets was 8.19 M USD — a change of -95.21% (lower).

Total Assets

392,265.00USD

YoY

-95.21%

Last updated:

Total Assets of Scopus Biopharma is 2022 392,265.00 USD. Total Assets of Scopus Biopharma was 2021 8.19 M USD. It decreases by -95.21% lower compared to the previous year.

The Scopus Biopharma Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2017
212,870.00 USD
Jan 1, 2018
132,638.00 USD
Jan 1, 2019
771,682.00 USD
Jan 1, 2020
1.97 M USD
Jan 1, 2021
8.19 M USD
Jan 1, 2022
392,265.00 USD
The Scopus Biopharma Total Assets history
YEARTotal AssetsYoY
392,265.00USD-95.21%
8.19 MUSD+314.76%
1.97 MUSD+155.81%
771,682.00USD+481.80%
132,638.00USD-37.69%
212,870.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scopus Biopharma Stock analysis

What does Scopus Biopharma do? Scopus Biopharma Inc develops therapeutics targeting diseases with unmet medical needs, focusing on immuno-oncology programs. The company's Duet Platform utilizes bifunctional oligonucleotides to activate antigen-presenting cells and alleviate tumor immunosuppression. DUET-01 is in development for relapsed or refractory B-cell non-Hodgkin lymphoma, while DUET-02 targets solid tumors like prostate or kidney cancers through systemic delivery. The firm's products are developed for clinical trials and potential future commercialization. Scopus Biopharma's revenue streams are not disclosed in the business description, but the company is developing its Duet Platform products for potential licensing or partnership agreements. The immuno-oncology focus and bifunctional oligonucleotide platform represent the core of the company's product pipeline. The company's products target specific cancer types with unmet medical needs, aiming to jump-start T cell-mediated immune responses. The company's development pipeline includes DUET-01 for B-cell non-Hodgkin lymphoma and DUET-02 for solid tumors. The Duet Platform's three bifunctional oligonucleotides (DUET-01, DUET-02, DUET-03) form the foundation of its therapeutic approach. The firm is developing these products for potential commercialization after successful clinical trials and regulatory approvals. Scopus Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Scopus Biopharma stock

Total Assets of Scopus Biopharma is 392,265.00 USD in 2022.

Total Assets of Scopus Biopharma changed from 8.19 M USD to 392,265.00 USD, representing a -95.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets Scopus Biopharma since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's Scopus Biopharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Scopus Biopharma

All Key Metrics — Scopus Biopharma